Lung & Respiratory Disease Clinical Trials Update: Week 27, 2026

Published July 3, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Depemokimab in Participants of 6 to 11 Years of Age

This Phase 3 study is exploring depemokimab as an additional treatment for children aged 6 to 11 with asthma linked to type 2 inflammation. The goal is to improve asthma control by targeting the root cause of inflammation, which may help reduce symptoms and lower the risk of flare-ups. Although still not recruiting, the study plans to enroll 30 children and could lead to a new treatment option with fewer side effects.

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

This large Phase 3 trial is testing lebrikizumab, a biologic drug, for adolescents whose asthma remains uncontrolled despite current treatments. With 346 participants across many countries, the study monitors the effects of this medicine over two years. If successful, it may offer teenagers better symptom control and fewer asthma attacks.

Ongoing Lung Decline With Age Intensified Response

This Phase 2 trial is looking at fisetin, a pill aimed at improving lung health in adults aged 60 and older who experience natural lung decline with age. By targeting the aging process in the lungs, fisetin could help slow breathing difficulties that come with getting older. The study will include both smokers and non-smokers and enroll about 40 participants.

A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in Adults

This study compares three treatment options for adults with obstructive sleep apnea: the standard PAP machine, a dental device, and a combination medication. It aims to find out which treatment works best and is easiest for patients to use regularly. With 2400 participants planned, this research could make managing sleep apnea more personalized and effective.

SMART@Home Feasibility Trial

This trial is testing a new digital app and tools for teenagers aged 12 to 17 with asthma to help track and manage their symptoms from home. The goal is to improve communication between patients and doctors, making asthma care more responsive and tailored. The 6-month pilot phase is recruiting 40 participants in the United States.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.